Sally Frank, NP
Family · Bismarck, NDNPI 1215248547
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 265 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,320, 6.9 times the $191 reported in 2021. Among family clinicians in ND with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 265 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$583
- Lilly USA, LLC$546
- Pfizer$448
- AbbVie$428
- Novo Nordisk$343
- Astellas Pharma US Inc$316
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,16698%
- Education$952%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 38 | $583 |
| Lilly USA, LLC | 38 | $546 |
| Pfizer | 31 | $448 |
| AbbVie | 29 | $428 |
| Novo Nordisk | 23 | $343 |
| Astellas Pharma US Inc | 14 | $316 |
| AstraZeneca | 10 | $243 |
| Boehringer Ingelheim | 13 | $197 |
| Bayer | 9 | $156 |
| Novartis | 9 | $138 |
| E.r. Squibb & Sons, L.L.C. | 8 | $129 |
| Abbott | 8 | $126 |
| Phathom Pharmaceuticals, Inc. | 5 | $69 |
| Exact Sciences | 3 | $50 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $47 |
| Daiichi Sankyo Inc. | 3 | $46 |
| Alkermes, Inc. | 3 | $45 |
| GSK | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Actelion Pharmaceuticals US, Inc. | 2 | $35 |
| Lexicon Pharmaceuticals, Inc. | 2 | $34 |
| Johnson & Johnson | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Radius Health, Inc. | 1 | $26 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $25 |
| Biogen | 1 | $24 |
| Medtronic | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Madrigal Pharmaceuticals | 1 | $17 |
| Merck | 1 | $14 |
How this compares
$4,261 in reported general payments places this provider in the 95th percentile of 496 family providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 231 | $239,578 |
| JardianceEmpagliflozin | 228 | $224,293 |
| EliquisApixaban | 197 | $169,274 |
| TrulicityDulaglutide | 85 | $91,728 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $47,508 |
| XareltoRivaroxaban | 43 | $35,608 |
| MounjaroTirzepatide | 25 | $30,134 |
| MyrbetriqMirabegron | 37 | $25,997 |
| FarxigaDapagliflozin Propanediol | 24 | $24,962 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $17,501 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $16,963 |
| Novolog FlexpenInsulin Aspart | 45 | $14,751 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $14,210 |
| JanuviaSitagliptin Phosphate | 20 | $13,968 |
| Spiriva RespimatTiotropium Bromide | 26 | $13,261 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $343 | $239,578231 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $197 | $237,554254 claims |
| PfizerEliquis, Abrysvo | $448 | $177,086223 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $546 | $121,862110 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $43 | $56,57878 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $243 | $42,01569 claims |
| Johnson & JohnsonXarelto | $30 | $35,60843 claims |
| Astellas Pharma US IncMyrbetriq | $316 | $25,99737 claims |
| MerckJanuvia | $14 | $13,96820 claims |
| AbbVieSynthroid | $428 | $9,031115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 496 family providers in North Dakota.
Other family in Bismarck
- Courtney WoodburyBismarck$8K
- Monica GoetzBismarck$8K
- Elizabeth ScheurerBismarck$6K
- Kayla HolzerBismarck$5K
- Amanda AllmarasBismarck$5K
- Kathryn StensgardBismarck$5K
- Amy GotvasleeBismarck$4K
- Michelle MaierBismarck$4K
- Tanya GuthmillerBismarck$4K
- Amanda HelmBismarck$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.